Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT03633045 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Observational Study of Ibrutinib Use in CLL

Start date: September 1, 2018
Study type: Observational

IB-RU-SCOPE is a "routine-clinical practice" oriented cohort observational study of ibrutinib efficacy and safety in approx. 70 patients with chronic lymphocytic leukemia in the Russian Federation

NCT ID: NCT03628053 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Start date: January 17, 2019
Phase: Phase 3
Study type: Interventional

This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.

NCT ID: NCT03627208 Enrolling by invitation - Clinical trials for Leukemia, Lymphoblastic, Acute

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

Start date: August 22, 2018
Study type: Observational

Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It occurs when a bone marrow cell develops errors in its DNA. Certain tests are used to help detect the disease. But the results of these tests often disagree. Researchers want to review the results of tests of bone marrow and cerebrospinal fluid (CSF) from people with ALL. They want to try to find the best ways to detect the disease. Objective: To compare results of certain bone marrow and CSF tests for detecting ALL, in order to see how much and how often the results disagreed. Eligibility: Children and young adults with ALL or lymphoblastic lymphoma who were enrolled in certain previous studies and consented for their data to be used. Design: Investigators will review participants medical records. They will collect data like the participant s gender, age, and when their tests were done. They will also collect results from tests like: Bone marrow tests Flow cytometry tests Imaging CSF cell count All of the stored data will be labeled by a code that only the study team at the research site can link to the participant. Data will be stored in password protected computers.

NCT ID: NCT03624530 Recruiting - Clinical trials for Minimal Residual Disease

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Start date: August 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Relapse remains a major cause of treatment failure even after allo-HSCT. The prevention of relapse is essential for improving the outcome of Ph+ ALL. Our previous clinical trial (ID: NCT01883219) demonstrated that pre-emptive tyrosine kinase inhibitor (TKIs) administration based on minimal residual disease (MRD) and BCR-ABL mutation after allo-HSCT might reduce the incidence of relapses and improve survival for patients with Ph+ ALL. Moreover, our result suggested that Ph+ ALL with MRD positive pre-transplants had the higher rate of molecular biology relapse. In this study, we will evaluate the safety and efficacy of prophylactic TKI therapy post-transplants on Ph+ ALL undergoing allo-HSCT with MRD positive pre-transplants.

NCT ID: NCT03624036 Not yet recruiting - Clinical trials for Relapsed/Refractory Chronic Lymphocytic Leukemia

Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia

Start date: October 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety (Phase 1) and efficacy (Phase 2) of KTE-C19 in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL).

NCT ID: NCT03622788 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant

Start date: December 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well cytokine-treated veto cells work in treating participants with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. cytokine-treated veto cells may help the transplanted donor cells to develop and grow in recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue attacks the tissues of the recipient's body).

NCT ID: NCT03620058 Not yet recruiting - Clinical trials for Refractory Acute Lymphoblastic Leukemia

CART22 Alone or in Combination With huCART19 for ALL

Start date: September 2018
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.

NCT ID: NCT03615105 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.

NCT ID: NCT03614858 Recruiting - Leukemia, B-cell Clinical Trials

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Start date: September 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

NCT ID: NCT03613727 Not yet recruiting - Multiple Myeloma Clinical Trials

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.